In theory, 2020 should have been a great year for Pfizer (NYSE: PFE) shareholders. The big drugmaker, along with its German partner BioNTech (NASDAQ: BNTX), became the first to secure U.S. emergency use authorization for a coronavirus vaccine. Pfizer also wrapped up a long-awaited deal to spin off its Upjohn unit, paving the way for stronger growth.
But theories don’t always fare so well in the real world. Despite its major achievements last year, Pfizer’s shares actually slipped nearly 1%. Pfizer was a surprising loser in 2020. However, the pharma stock could win big time in 2021.